2nd Quarter - Report — CROHN'S & COLITIS FOUNDATION for CROHN'S & COLITIS FOUNDATION (2026)

Firm

CROHN'S & COLITIS FOUNDATION

Client

CROHN'S & COLITIS FOUNDATION

Income

—

Expenses

$40,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FY 2027 Funding for medical research at the NIH and CDC FY 2027 Appropriations - DoD Congressionally Directed Medical Research Program S 864/ HR 6423 Help Ensure Lower Patient Copays Act S 526 Pharmacy Benefit Manager Transparency Act HR 5509/ S 2903: Safe Step Act S 3304 / HR 5684 Medical Foods and Formula Access Act CMS - Interoperability Standards and Prior Authorization for Drugs proposed rule CMS - RFI on step therapy in Medicare CMS - Reimbursement for infused biosimilars CMS - Medicare Competitive bidding for ostomy supplies FDA - Approvals for pediatric IBD medications HHS - FY 2027 NBPP

Lobbyist	Covered position, as disclosed
ERIN HENNESSEY MCKEON	—

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH)

Bills named: H.R. 5509 (119th), H.R. 5684 (119th), H.R. 6423 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.